PATENT CLAIM ANALYSIS

Application Number: 16060109
Application Type: Utility
Filing Date: 2018-06
Publication Date: 2018-12
Patent Classification: ["514", "004800"]

Abstract:
The invention provides compositions and methods for inhibiting protein-protein interactions with cap-binding protein 80 (CBP80). In one embodiment, the invention provides compositions comprising linear and macrocylic peptides. In one embodiment, the invention provides methods for treating cancer, heart disease, autoimmune disorders, obesity, diabetes, or chronic inflammation disorders associated with the PGC1 family of co-activators.

Claim (Index 19):
The peptide of  claim 11 , wherein X 9  is selected from the group consisting of a lysine, ornithine and a 2,4-diaminobutyric acid derivative bearing a side-chain electrophilic group capable of reacting with cysteine.

Metadata:
- Claim Count in Document: 2.0
- Percentile: 94.0
- Lexical Diversity: 1.53488
- Patent Class: 514.0
- Transitional Phrase Type: closed
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['14398260', '15941030', '14800627', '14118545', '09825517']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8589371635687109
- 35 USC 102 Novelty (BERT): 0.5884964128188668
- Combined Prediction Score: 0.8318930884937265
- Mean Citation Score: 553.978646
- Max Citation Score: 558.4818
- Similarity Product: 399.61689482624536

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 0
- Combined Label: 1
- Label 101 Adjusted: 0

Dataset: test